Roche partners with Zealand Pharma to push forward obesity drug

LONDON — Looking to expand its obesity offerings, Roche on Wednesday said it had partnered with Zealand Pharma to license an experimental weight loss drug for $1.65 billion in upfront cash.

The Swiss pharma giant and the Danish biotech will now work together to develop Zealand’s drug candidate petrelintide, aiming to test it on its own and in combination with Roche’s experimental CT-388.

The agreement includes additional payments based on certain clinical and sales goals being met, totaling up to $5.3 billion.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Potential Cannabis Buyouts

You’re reading this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight

December 19, 2024

AstraZeneca targets obesity market with Eccogene partnership – Pharmaceutical Technology

EC5004 is a GLP-1 inhibitor, a class of drugs developed to treat obesity and T2D. Credit: Alexanderstock23 via www.shutterstock.com AstraZeneca has fortified its participation in

November 9, 2023

SCALE-UP Counts program shows text messaging can be an effective tool for public health

An examination of the SCALE-UP Counts program was recently published in the journal Pediatrics.

August 25, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.